Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IOBT
- Price
- 0.86
- Stock movement down
- -0.00 (-0.09%)
- Company name
- IO Biotech Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 56.46M
- Ent value
- -6.35M
- Price/Sales
- 50.86
- Price/Book
- 0.78
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -45.76%
- 3 year return
- -51.34%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IOBT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 50.86 |
| Price to Book | 0.78 |
| EV to Sales | -5.72 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.88M |
| EPS (TTM) | -1.37 |
| FCF per share (TTM) | -1.30 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.11M |
| Gross profit (TTM) | 484.00K |
| Operating income (TTM) | -96.42M |
| Net income (TTM) | -90.34M |
| EPS (TTM) | -1.37 |
| EPS (1y forward) | -1.29 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 43.60% |
| Operating margin (TTM) | -8686.22% |
| Profit margin (TTM) | -8138.74% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 80.19M |
| Net receivables | 964.00K |
| Total current assets | 86.24M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 89.94M |
| Accounts payable | 5.26M |
| Short/Current long term debt | 2.02M |
| Total current liabilities | 16.05M |
| Total liabilities | 17.38M |
| Shareholder's equity | 72.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -85.52M |
| Capital expenditures (TTM) | 145.00K |
| Free cash flow (TTM) | -85.66M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -124.50% |
| Return on Assets | -100.44% |
| Return on Invested Capital | -123.32% |
| Cash Return on Invested Capital | -116.93% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.85 |
| Daily high | 0.89 |
| Daily low | 0.85 |
| Daily Volume | 29K |
| All-time high | 16.31 |
| 1y analyst estimate | 9.00 |
| Beta | 0.42 |
| EPS (TTM) | -1.37 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| IOBT | S&P500 | |
| Current price drop from All-time high | -94.75% | -12.89% |
| Highest price drop | -95.41% | -56.47% |
| Date of highest drop | 26 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -82.65% | -11.07% |
| Avg time to new high | 862 days | 12 days |
| Max time to new high | 861 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
56.46M
Marketcap category
Small-cap
Description
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Employees
74
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page